PALLIATIVE RADIATION DURING PEMETREXED PLUS CISPLATIN FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PATIENT SAFETY IN THE JMDB AND PARAMOUNT TRIALS

被引：0
|
作者：
Scagliotti, G. V. [1 ]
Gridelli, C. [2 ]
de Marinis, F. [3 ]
Biesma, B. [4 ]
Reck, M. [5 ]
San Antonio, B. [6 ]
Zimmermann, A. H. [7 ]
Visseren-Grul, C. [8 ]
Chouaki, N. [9 ]
Paz-Ares, L. [10 ]
机构：
[1] Univ Turin, Turin, Italy
[2] San Giuseppe Moscati Hosp, Dept Oncol Hematol, Avellino, Italy
[3] San Camillo Forlanini Hosp, Oncol Pulm Unit 1, Rome, Italy
[4] Jeroen Bosch Hosp, Dept Pulm Dis, sHertogenbosch, Netherlands
[5] Hosp Grosshansdorf, Grosshansdorf, Germany
[6] Eli Lilly & Co, Oncol, Madrid, Spain
[7] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[8] Eli Lilly & Co, Oncol Thorac, Houten, Netherlands
[9] Eli Lilly & Co, Oncol Thorac, Paris, France
[10] Seville Univ Hosp, Seville, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2014年 / 9卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
113P
引用
收藏
页码：S45 / S45
页数：1
相关论文
共 50 条
  • [41] A phase II trial of first-line bevacizumab in combination with pemetrexed and carboplatin in advanced nonsquamous non-small cell lung cancer (NSCLC)
    Skaff, Z. G.
    Hageboutros, A.
    Krieger, K.
    Coakley, S.
    Somer, R.
    Stevenson, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Anlotinib combined with pemetrexed and carboplatin as first-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC): ALTER L012.
    Wang, Qiming
    Yang, Xiuli
    Ma, Tianjiang
    Yang, Qiumin
    Zhang, Chenghui
    Chen, Yunfang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Safety and Efficacy of First-Line Pemetrexed Versus Bevacizumab-Containing Regimens in Advanced Non-Small Cell Lung Cancer
    Syrigos, K.
    Charpidou, A.
    Grapsa, D.
    Vassos, D.
    Tsimpoukis, S.
    Tsagouli, S.
    Gkiozos, I.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S902 - S903
  • [44] PEMETREXED MAINTENANCE TREATMENT IN ADVANCED NON SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Megaiz, Ahlem
    Bousahba, Abdelkader
    Rabah, Aicha
    Zemmour, Amel
    Ahed-Messaoud, Malika
    Ghazli, Soumia
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S588 - S589
  • [45] First-line treatment for non-small cell lung cancer
    Pinn, Stephen
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (01) : 10 - 10
  • [46] 65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC).
    Schuette, Wolfgang
    Nagel, Sylke
    Schneider, Claus-Peter
    Engel-Riedel, Walburga
    Schumann, Christian
    Kohlhaeufl, Martin
    Serke, Monika
    Hoeffken, Gert
    Kortsik, Cornelius
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Favorable benefit to risk profile for pemetrexed plus cisplatin versus gemcitabine plus cisplatin in a large phase III study of first-line therapy in advanced non-small cell lung cancer
    Scaqliotti, G.
    Park, K.
    Patil, S.
    Rolski, J.
    Gorksel, T.
    Gans, S. J. M.
    Martins, R.
    Visseren-Grul, C.
    Peterson, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 363 - 363
  • [48] Comparison of pemetrexed plus cisplatin versus pemetrexed plus carboplatin in the initial treatment of locally advanced or metastatic non-small cell lung cancer
    Pereira, A. A. R.
    Lessa, R. C.
    Souza, C. E. P.
    Pinto, F. A. I.
    Gagliato, D. M.
    Santos, E. S.
    Fanelli, M. F.
    Rinck, J. A.
    Dettino, A. A.
    Nicolau, U. R.
    Chinen, L. T. D.
    de Lima, V. C. C.
    Pereira, J. R.
    Cruz, M. R. D. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] Cisplatin (CDDP) plus vinorelbine (VRB) as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): molecular correlates
    Provencio, M.
    Blanco, R.
    Alberola, V.
    Delgado, J. R.
    Diz, P.
    Almenarez, J. A.
    Lopez-Vivanco, G.
    Gonzalez-Larriba, J. L.
    Martin, G.
    Rosell, R.
    EJC SUPPLEMENTS, 2007, 5 (04): : 384 - 384
  • [50] What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?
    Ricciuti, Biagio
    Awad, Mark M.
    CANCER JOURNAL, 2020, 26 (06): : 485 - 495
12345